These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

352 related items for PubMed ID: 18363646

  • 1. Reduction of albuminuria by angiotensin receptor blocker beyond blood pressure lowering: evaluation in megsin/receptor for advanced glycation end products/inducible nitric oxide synthase triple transgenic diabetic nephropathy mouse model.
    Ohtomo S, Ito M, Izuhara Y, Van Ypersele De Strihou C, Miyata T.
    Nephrology (Carlton); 2008 Dec; 13(6):517-21. PubMed ID: 18363646
    [Abstract] [Full Text] [Related]

  • 2. Is renoprotection by angiotensin receptor blocker dependent on blood pressure?: the Saitama Medical School, Albuminuria Reduction in Diabetics with Valsartan (STAR) study.
    Katayama S, Yagi S, Yamamoto H, Yamaguchi M, Izumida T, Noguchi Y, Inaba M, Inukai K.
    Hypertens Res; 2007 Jun; 30(6):529-33. PubMed ID: 17664856
    [Abstract] [Full Text] [Related]

  • 3. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model.
    Tominaga N, Robert A, Izuhara Y, Ohtomo S, Dan T, Chihara K, Kurokawa K, Van Ypersele de Strihou C, Miyata T.
    Nephrology (Carlton); 2009 Sep; 14(6):581-7. PubMed ID: 19712258
    [Abstract] [Full Text] [Related]

  • 4. A novel Sartan derivative with very low angiotensin II type 1 receptor affinity protects the kidney in type 2 diabetic rats.
    Izuhara Y, Sada T, Yanagisawa H, Koike H, Ohtomo S, Dan T, Ito S, Nangaku M, van Ypersele de Strihou C, Miyata T.
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1767-73. PubMed ID: 18658044
    [Abstract] [Full Text] [Related]

  • 5. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 6. Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
    Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL, Januszewicz A.
    J Hypertens; 2006 Feb; 24(2):403-8. PubMed ID: 16508590
    [Abstract] [Full Text] [Related]

  • 7. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K.
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [Abstract] [Full Text] [Related]

  • 8. Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy.
    Schjoedt KJ, Lajer M, Andersen S, Tarnow L, Rossing P, Parving HH.
    Scand J Clin Lab Invest; 2006 Jul; 66(3):173-80. PubMed ID: 16714246
    [Abstract] [Full Text] [Related]

  • 9. Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy.
    Mima A, Arai H, Matsubara T, Abe H, Nagai K, Tamura Y, Torikoshi K, Araki M, Kanamori H, Takahashi T, Tominaga T, Matsuura M, Iehara N, Fukatsu A, Kita T, Doi T.
    Diabetes; 2008 Jun; 57(6):1712-22. PubMed ID: 18285555
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy?
    Miyata T, Izuhara Y.
    Ann N Y Acad Sci; 2008 Apr; 1126():141-6. PubMed ID: 18448808
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Candesartan reduced advanced glycation end-products accumulation and diminished nitro-oxidative stress in type 2 diabetic KK/Ta mice.
    Fan Q, Liao J, Kobayashi M, Yamashita M, Gu L, Gohda T, Suzuki Y, Wang LN, Horikoshi S, Tomino Y.
    Nephrol Dial Transplant; 2004 Dec; 19(12):3012-20. PubMed ID: 15574998
    [Abstract] [Full Text] [Related]

  • 17. Nilvadipine attenuates mesangial expansion and glomerular hypertrophy in diabetic db/db mice, a model for type 2 diabetes.
    Moriyama T, Oka K, Ueda H, Imai E.
    Clin Exp Nephrol; 2004 Sep; 8(3):230-6. PubMed ID: 15480900
    [Abstract] [Full Text] [Related]

  • 18. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/iNOS transgenic mice.
    Inagi R, Yamamoto Y, Nangaku M, Usuda N, Okamato H, Kurokawa K, van Ypersele de Strihou C, Yamamoto H, Miyata T.
    Diabetes; 2006 Feb; 55(2):356-66. PubMed ID: 16443768
    [Abstract] [Full Text] [Related]

  • 19. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S, Takeuchi K, Mori T, Nako K, Tsubono Y, Ito S.
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin II provokes podocyte injury in murine model of HIV-associated nephropathy.
    Ideura H, Hiromura K, Hiramatsu N, Shigehara T, Takeuchi S, Tomioka M, Sakairi T, Yamashita S, Maeshima A, Kaneko Y, Kuroiwa T, Kopp JB, Nojima Y.
    Am J Physiol Renal Physiol; 2007 Oct; 293(4):F1214-21. PubMed ID: 17652372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.